CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma
CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma
复制标题
DOI：
10.1016/j.canlet.2011.10.012
复制
发表时间：
2012-02-28
期刊：
影响因子：
9.7
通讯作者：
Yoon, Seung Kew
中科院分区：
文献类型：
--
作者：
Piao, Lian Shu;Hur, Wonhee;Yoon, Seung Kew
CD 133是与各种癌症中的放射抗性和化学抗性相关的癌症干细胞（CSC）标志物。在本研究中，与CD 133（-）细胞相比，辐射暴露后表达CD 133的肝癌细胞显示出更高的MAPK/PI 3 K信号通路活化和活性氧水平降低。异种移植模型的体内研究显示，与CD 133（-）组相比，照射CD 133（+）细胞注射裸鼠的肿瘤形成增加，表明CD 133有助于HCC的放射抗性。因此，表达CD 133的肝癌细胞具有抗凋亡和放射抗性特性，这可能有助于改善抗癌治疗，包括HCC的化疗/放疗。皇冠版权所有（C）2011由爱思唯尔爱尔兰有限公司出版。保留所有权利。
CD133 is a cancer stem-cell (CSC) marker associated with radioresistance and chemoresistance in various cancers. In the present study, CD133-expressing liver cancer cells following radiation exposure showed higher activation of MAPK/PI3K signaling pathway and reduction in reactive oxygen species levels compared to CD133(-) cells. The in vivo study with a xenograft model showed increased tumor formation in irradiated CD133(+) cell-injected nude mice compared to the CD133(-) group, suggesting that CD133 contributes to radioresistance in HCC. Therefore, CD133-expressing liver cancer cells have anti-apoptotic and radioresistance properties that may be useful to improve anti-cancer treatments, including chemotherapy/radiotherapy of HCC. Crown Copyright (C) 2011 Published by Elsevier Ireland Ltd. All rights reserved.